The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Monopar Therapeutics Inc(NASDAQ:MNPR) 
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for t...
Website: https://www.monopartx.com/
Founded: 2014
Full Time Employees: 6
CEO: Chandler Drew Robinson
Sector: Healthcare
Industry: Biotechnology
Monopar Therapeutics Number of Twitter Followers
Monopar Therapeutics Op Cashflow Per Share ttm
Monopar Therapeutics Free Cashflow Per Share ttm
Monopar Therapeutics Cash Per Share ttm
Monopar Therapeutics (GAAP) P/E ratio ttm
Monopar Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.